| Drug Name: | Ranitidine (66357-35-5) |
|---|---|
| PubChem ID: | 3001055 |
| SMILES: | CN/C(=C[N+](=O)[O-])/NCCSCC1=CC=C(O1)CN(C)C |
| InchiKey: | VMXUWOKSQNHOCA-UKTHLTGXSA-N |
| Therapeutic Category: | Anti-Ulcer Agents, Gastrointestinal Agents, Histamine Agents, Histamine Antagonists, Histamine H2 Antagonists, Neurotransmitter Agents |
| Molecular Weight (dalton) | : | 314.411 |
| LogP | : | 1.459 |
| Ring Count | : | 1 |
| Hydrogen Bond Acceptor Count | : | 7 |
| Hydrogen Bond Donor Count | : | 2 |
| Total Polar Surface Area | : | 83.58 |
This panel provides information on interacting drugs and their ADRs along with references
| Interacting drug | Toxicity | Interaction Type | Mechanism | Reference |
|---|---|---|---|---|
| Quinidine (56-54-2) | Arrhythmia | Antagonistic | It was originally suggested that the ranitidine inhibits the metabolism of the quinidine by the liver so that it is cleared more slowly. | Quinidine-ranitidine adverse reaction |
This panel provides drug-protein interaction and their ADRs along with references
| Toxicity | Interacting Protein | Mechanism | Reference |
|---|---|---|---|
| Constipation | Kappa-Type opioid receptor (P41145) | Not Available | Large-scale prediction and testing of drug activity on side-effect targets |
| Constipation | Sodium-dependent dopamine transporter (Q01959) | Not Available | Large-scale prediction and testing of drug activity on side-effect targets |
| Malabsorption Of Protein-Bound Cobalamin | Gastric intrinsic factor (P27352) | Oral ranitidine resulted in a non significant decrease of IF concentration and IF output@which was responsible for malabsorption of protein-bound cobalamin [ ADR Type 1 ] | Effect of ranitidine on secretion of gastric intrinsic factor and absorption of vitamin B 12 |
This panel provides drug-food interactions and their ADRs along with references
| Food | Toxicity | Reference |
|---|
This panel provides information on metabolites and their ADRs along with references
| Metabolite | Toxicity | Place of Metabolism | Mechanism | Reference |
|---|
This panel provides information on drug category